Trade-Ideas LLC identified

PRA Health

(

PRAH

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified PRA Health as such a stock due to the following factors:

  • PRAH has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $23.1 million.
  • PRAH has traded 1,839 shares today.
  • PRAH is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PRAH with the Ticky from Trade-Ideas. See the FREE profile for PRAH NOW at Trade-Ideas

More details on PRAH:

PRA Health Sciences, Inc., a contract research organization, provides various product development services for pharmaceutical and biotechnology companies worldwide. Currently there are 4 analysts that rate PRA Health a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for PRA Health has been 261,300 shares per day over the past 30 days. PRA Health has a market cap of $2.9 billion and is part of the health care sector and health services industry. Shares are up 97% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates PRA Health as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins.

Highlights from the ratings report include:

  • Powered by its strong earnings growth of 1750.00% and other important driving factors, this stock has surged by 86.66% over the past year, outperforming the rise in the S&P 500 Index during the same period.
  • The revenue growth came in higher than the industry average of 5.1%. Since the same quarter one year prior, revenues slightly increased by 6.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • In comparison to the other companies in the Life Sciences Tools & Services industry and the overall market, PRA HEALTH SCIENCES INC's return on equity is significantly below that of the industry average and is below that of the S&P 500.
  • The gross profit margin for PRA HEALTH SCIENCES INC is currently lower than what is desirable, coming in at 32.78%. Regardless of PRAH's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 5.86% trails the industry average.
  • The debt-to-equity ratio of 1.34 is relatively high when compared with the industry average, suggesting a need for better debt level management. Along with the unfavorable debt-to-equity ratio, PRAH maintains a poor quick ratio of 0.89, which illustrates the inability to avoid short-term cash problems.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.